For example, a cognitively unimpaired individual with positive Αβ (Α+) and tau (T+) biomarkers is classified as ‘preclinical AD’ by the NIA-AA criteria2, while the IWG criteria3 would label such an individual ‘at risk for progression to AD’ (Fig. 1). Here, MAPT is linked to Alzheimer disease.